John Collinge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8244317/publications.pdf

Version: 2024-02-01

140 papers	16,902 citations	23567 58 h-index	15266 126 g-index
149 all docs	149 docs citations	149 times ranked	11690 citing authors

#	Article	IF	Citations
1	Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature, 1996, 383, 685-690.	27.8	1,649
2	Prion Diseases of Humans and Animals: Their Causes and Molecular Basis. Annual Review of Neuroscience, 2001, 24, 519-550.	10.7	1,194
3	A General Model of Prion Strains and Their Pathogenicity. Science, 2007, 318, 930-936.	12.6	937
4	Homozygous prion protein genotype predisposes to sporadic Creutzfeldtâ€“Jakob disease. Nature, 1991, 352, 340-342.	27.8	838
5	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
6	Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis. Science, 2003, 302, 871-874.	12.6	673
7	Structural variation in amyloid-Î² fibrils from Alzheimer's disease clinical subtypes. Nature, 2017, 541, 217-221.	27.8	528
8	Variant Creutzfeldt-Jakob disease. Lancet, The, 1999, 354, 317-323.	13.7	483
9	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	27.8	457
10	Evidence for human transmission of amyloid-Î² pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	27.8	418
11	Balancing Selection at the Prion Protein Gene Consistent with Prehistoric Kurulike Epidemics. Science, 2003, 300, 640-643.	12.6	347
12	Kuru in the 21st centuryâ€”an acquired human prion disease with very long incubation periods. Lancet, The, 2006, 367, 2068-2074.	13.7	345
13	BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO Journal, 2002, 21, 6358-6366.	7.8	317
14	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
15	Molecular classification of sporadic Creutzfeldtâ€“Jakob disease. Brain, 2003, 126, 1333-1346.	7.6	301
16	Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature, 2011, 470, 540-542.	27.8	269
17	Interaction between prion protein and toxic amyloid Î² assemblies can be therapeutically targeted at multiple sites. Nature Communications, 2011, 2, 336.	12.8	263
18	A systematic review of prion therapeutics in experimental models. Brain, 2006, 129, 2241-2265.	7.6	250

#	Article	IF	Citations
19	Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected Mice. Neuron, 2007, 53, 325-335.	8.1	246
20	Amyloid Î²-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. Journal of Neuroscience, 2010, 30, 14411-14419.	3.6	232
21	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology, The, 2009, 8, 334-344.	10.2	226
22	Mammalian prions and their wider relevance in neurodegenerative diseases. Nature, 2016, 539, 217-226.	27.8	193
23	Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10238-10243.	7.1	174
24	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
25	A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure. New England Journal of Medicine, 2009, 361, 2056-2065.	27.0	157
26	mGlu5 receptors and cellular prion protein mediate amyloid-Î²-facilitated synaptic long-term depression in vivo. Nature Communications, 2014, 5, 3374.	12.8	157
27	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
28	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	27.8	144
29	Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nature Genetics, 1995, 9, 197-201.	21.4	141
30	Structural mobility of the human prion protein probed by backbone hydrogen exchange. Nature Structural Biology, 1999, 6, 740-743.	9.7	140
31	Genetic risk factors for variant Creutzfeldtâ€“Jakob disease: a genome-wide association study. Lancet Neurology, The, 2009, 8, 57-66.	10.2	131
32	Variant Creutzfeldtâ€“Jakob Disease in a Patient with Heterozygosity at PRNP Codon 129. New England Journal of Medicine, 2017, 376, 292-294.	27.0	127
33	Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications, 2014, 5, 4347.	12.8	126
34	Transmission of amyloid-Î² protein pathology from cadaveric pituitary growth hormone. Nature, 2018, 564, 415-419.	27.8	122
35	Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochemical Journal, 2008, 416, 297-305.	3.7	118
36	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	27.0	113

#	Article	IF	Citations
37	Amyloid-Î² nanotubes are associated with prion protein-dependent synaptotoxicity. Nature Communications, 2013, 4, 2416.	12.8	112
38	PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathologica, 2020, 139, 503-526.	7.7	110
39	Tissue Handling in Suspected Creutzfeldtâ€Jakob Disease (CJD) and Other Human Spongiform Encephalopathies (Prion Diseases). Brain Pathology, 1995, 5, 319-322.	4.1	103
40	An enzymeâ€“detergent method for effective prion decontamination of surgical steel. Journal of General Virology, 2005, 86, 869-878.	2.9	103
41	R47H TREM2 variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.8	94
42	Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain, 2006, 129, 676-685.	7.6	93
43	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
44	Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	7.6	92
45	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain, 2006, 129, 1557-1569.	7.6	91
46	Molecular pathology of human prion disease. Acta Neuropathologica, 2011, 121, 69-77.	7.7	90
47	PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit. Human Mutation, 2010, 31, E1551-E1563.	2.5	85
48	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathologica, 2015, 130, 511-523.	7.7	79
49	The Medical Research Council Prion Disease Rating Scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain, 2013, 136, 1116-1127.	7.6	77
50	Prion Strain Mutation and Selection. Science, 2010, 328, 1111-1112.	12.6	76
51	Pharmacological chaperone for the structured domain of human prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17610-17615.	7.1	71
52	The Residue 129 Polymorphism in Human Prion Protein Does Not Confer Susceptibility to Creutzfeldt-Jakob Disease by Altering the Structure or Global Stability of PrPC. Journal of Biological Chemistry, 2004, 279, 28515-28521.	3.4	68
53	Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10759-10764.	7.1	68
54	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease AÎ² Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	3.6	68

#	Article	IF	Citations
55	Prion Protein as a Toxic Acceptor of Amyloid-Î² Oligomers. Biological Psychiatry, 2018, 83, 358-368.	1.3	66
56	2.7â€‰Ã… cryo-EM structure of ex vivo RML prion fibrils. Nature Communications, 2022, 13, .	12.8	66
57	A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3725-3739.	4.0	65
58	PrP glycoforms are associated in a strain-specific ratio in native PrPSc. Journal of General Virology, 2005, 86, 2635-2644.	2.9	63
59	Genetic Factors in Mammalian Prion Diseases. Annual Review of Genetics, 2019, 53, 117-147.	7.6	63
60	PrP Antibodies Do Not Trigger Mouse Hippocampal Neuron Apoptosis. Science, 2012, 335, 52-52.	12.6	62
61	Elongated Oligomers Assemble into Mammalian PrP Amyloid Fibrils. Journal of Molecular Biology, 2006, 357, 975-985.	4.2	61
62	Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. Journal of General Virology, 2009, 90, 546-558.	2.9	58
63	Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biology, 2016, 6, 160035.	3.6	55
64	Definable Equilibrium States in the Folding of Human Prion Proteinâ€. Biochemistry, 2005, 44, 16649-16657.	2.5	51
65	Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test. JAMA Neurology, 2014, 71, 421.	9.0	51
66	A novel and rapid method for obtaining high titre intact prion strains from mammalian brain. Scientific Reports, 2015, 5, 10062.	3.3	51
67	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitinâ€“proteasome system. Acta Neuropathologica, 2016, 131, 411-425.	7.7	51
68	HLA-DQ7 antigen and resistance to variant CJD. Nature, 2001, 414, 269-270.	27.8	49
69	Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 692-694.	1.9	48
70	Potential human transmission of amyloid Î² pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	10.2	46
71	Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. Journal of General Virology, 2004, 85, 2471-2478.	2.9	45
72	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42

#	Article	IF	Citations
73	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	9.0	41
74	Ascertainment Bias Causes False Signal of Anticipation in Genetic Prion Disease. American Journal of Human Genetics, 2014, 95, 371-382.	6.2	40
75	A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biology, 2015, 5, 150165.	3.6	39
76	Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2008, 459, 197-227.	0.9	38
77	Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldtâ€“Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurology, The, 2022, 21, 342-354.	10.2	38
78	Structural features distinguishing infectious ex vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro. Scientific Reports, 2019, 9, 376.	3.3	37
79	Identification of a Compound That Disrupts Binding of Amyloid-Î² to the Prion Protein Using a Novel Fluorescence-based Assay. Journal of Biological Chemistry, 2015, 290, 17020-17028.	3.4	36
80	Preventing Prion Pathogenicity by Targeting the Cellular Prion Protein. Infectious Disorders - Drug Targets, 2009, 9, 48-57.	0.8	35
81	Conformational Properties of Î²-PrP. Journal of Biological Chemistry, 2009, 284, 21981-21990.	3.4	34
82	Isolation of Proteinase K-Sensitive Prions Using Pronase E and Phosphotungstic Acid. PLoS ONE, 2010, 5, e15679.	2.5	34
83	Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Molecular Psychiatry, 2021, 26, 5955-5966.	7.9	30
84	In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Human Molecular Genetics, 2014, 23, 5102-5108.	2.9	29
85	Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation. Journal of General Virology, 2006, 87, 2443-2449.	2.9	28
86	Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathogens, 2015, 11, e1004953.	4.7	27
87	Targeting glutamatergic and cellular prion protein mechanisms of amyloid Î²-mediated persistent synaptic plasticity disruption: Longitudinal studies. Neuropharmacology, 2017, 121, 231-246.	4.1	26
88	Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 693-700.	1.9	26
89	Î²-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91â€“110 that recognise native PrPSc. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 1438-1450.	2.3	25
90	The Risk of Prion Zoonoses. Science, 2012, 335, 411-413.	12.6	25

#	Article	IF	Citations
91	Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine. JAMA Neurology, 2016, 73, 1454.	9.0	25
92	Highly infectious prions are not directly neurotoxic. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23815-23822.	7.1	25
93	Quantitative EEG parameters correlate with the progression of human prion diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1061-1067.	1.9	24
94	Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia. British Journal of Psychiatry, 1991, 159, 857-859.	2.8	23
95	Predictive testing for inherited prion disease: report of 22 years experience. European Journal of Human Genetics, 2014, 22, 1351-1356.	2.8	23
96	Structural differences in amyloid-Î² fibrils from brains of nondemented elderly individuals and Alzheimer's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	23
97	Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Human Molecular Genetics, 2017, 26, ddx003.	2.9	22
98	Unswitched immunoglobulin M response prolongs mouse survival in prion disease. Journal of General Virology, 2009, 90, 777-782.	2.9	21
99	Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Scientific Reports, 2015, 5, 17742.	3.3	21
100	N-terminal Domain of Prion Protein Directs Its Oligomeric Association. Journal of Biological Chemistry, 2014, 289, 25497-25508.	3.4	20
101	Lessons of kuru research: background to recent studies with some personal reflections. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3689-3696.	4.0	18
102	Variant Creutzfeldt-Jakob Disease With Extremely Low Lymphoreticular Deposition of Prion Protein. JAMA Neurology, 2014, 71, 340.	9.0	17
103	Methods for Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2017, 1658, 311-346.	0.9	17
104	Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain, 2019, 142, 760-770.	7.6	16
105	PrP-grafted antibodies bind certain amyloid Î²-protein aggregates, but do not prevent toxicity. Brain Research, 2019, 1710, 125-135.	2.2	14
106	Sequence variation in intron of prion protein gene, crucial for complete diagnostic strategies. Human Mutation, 1996, 7, 280-281.	2.5	13
107	Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biology, 2020, 18, e3000725.	5.6	13
108	Identification of clinical target areas in the brainstem of prionâ€infected mice. Neuropathology and Applied Neurobiology, 2015, 41, 613-630.	3.2	11

#	Article	IF	Citations
109	Soluble AÎ² aggregates can inhibit prion propagation. Open Biology, 2017, 7, 170158.	3.6	11
110	Introduction. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3607-3612.	4.0	10
111	Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium. Journal of Molecular Biology, 2021, 433, 166878.	4.2	10
112	CJD discrepancy. Nature, 1991, 353, 802-802.	27.8	9
113	Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. American Journal of Medical Genetics Part A, 1995, 60, 44-52.	2.4	9
114	Evaluating the causality of novel sequence variants in the prion protein gene by example. Neurobiology of Aging, 2018, 71, 265.e1-265.e7.	3.1	9
115	Assessing initial MRI reports for suspected CJD patients. Journal of Neurology, 2022, 269, 4452-4458.	3.6	9
116	Neuroanatomical correlates of prion disease progression - a 3T longitudinal voxel-based morphometry study. NeuroImage: Clinical, 2017, 13, 89-96.	2.7	8
117	Rare structural genetic variation in human prion diseases. Neurobiology of Aging, 2015, 36, 2004.e1-2004.e8.	3.1	6
118	Human Prion Diseases. , 0, , 939-968.		6
119	Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Communications, 2019, 1, fcz012.	3.3	5
120	Structural effects of the highly protective V127 polymorphism on human prion protein. Communications Biology, 2020, 3, 402.	4.4	5
121	A novel prion protein variant in a patient with semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 890-892.	1.9	4
122	TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). Neurobiology of Aging, 2017, 59, 221.e1-221.e7.	3.1	4
123	Reply to: Intrinsic Toxicity of Antibodies to the Globular Domain of the Prion Protein. Biological Psychiatry, 2018, 84, e53-e54.	1.3	4
124	The most problematic symptoms of prion disease â€“ an analysis of carer experiences. International Psychogeriatrics, 2019, 31, 1181-1190.	1.0	4
125	NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression. Cells, 2021, 10, 3514.	4.1	4
126	Collinge et al. reply. Nature, 2016, 535, E2-E3.	27.8	3

#	Article	IF	Citations
127	Variants of PLCXD3 are not associated with variant or sporadic Creutzfeldt-Jakob disease in a large international study. BMC Medical Genetics, 2016, 17, 28.	2.1	3
128	Estimation of the number of inherited prion disease mutation carriers in the UK. European Journal of Human Genetics, 2022, 30, 1167-1170.	2.8	3
129	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
130	Physical, chemical and kinetic factors affecting prion infectivity. Prion, 2016, 10, 251-261.	1.8	2
131	A high-content neuron imaging assay demonstrates inhibition of prion disease-associated neurotoxicity by an anti-prion protein antibody. Scientific Reports, 2022, 12, .	3.3	2
132	Collinge et al. reply. Nature, 2016, 537, E9-E9.	27.8	1
133	Cognitive decline heralds onset of symptomatic inherited prion disease. Brain, 2021, 144, 989-998.	7.6	1
134	Human Prion Diseases. , 0, , 779-811.		0
135	Reminiscences and reflections on kuru, personal and scientific. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3613-3613.	4.0	0
136	O1â€05â€01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Alzheimer's and Dementia, 2012, 8, P92.	0.8	0
137	Blood Test for Variant Creutzfeldt-Jakob Diseaseâ€"Reply. JAMA Neurology, 2014, 71, 1054.	9.0	0
138	Inherited mtDNA variations are not strong risk factors in human prion disease. Neurobiology of Aging, 2015, 36, 2908.e1-2908.e3.	3.1	0
139	J9â€...Probing huntingtonâ€™s disease phenocopy syndromes with next-generation sequencing. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A78.2-A78.	1.9	0
140	Prions of Vertebrates. , 2021, , 707-713.		0